July 27, 2012 — Accuray Inc. announced the extension of its Emerald Service Program for the TomoTherapy system, which provides equipment protection and product updates that improve clinical uptime and enhance technology utilization, to customers throughout Japan. As part of its ongoing commitment to strengthening customer service globally, Accuray will now interact directly with TomoTherapy customers in Japan to provide service programs in the Japanese radiation oncology market.
"We are dedicated to helping advance radiation oncology treatment in Japan, and this is a significant move toward ensuring that our current and future customers throughout the country benefit from the highest quality customer service," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "We have seen clear traction for both the TomoTherapy and CyberKnife systems in Japan and believe that by managing the service program directly, we will be able to increase touch points with our customers, hear about their needs firsthand and reaffirm their confidence in our products."
The TomoTherapy system received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) in December 2004, and the first TomoTherapy system was installed in 2005. Presently there are 26 TomoTherapy systems and 25 CyberKnife robotic radiosurgery systems in use in Japan.
Previously, Hitachi Medical Corp. provided service and support for TomoTherapy customers in Japan. With the rollout of the Emerald Service Program, Hitachi Medical will transfer the regulatory approval and service business to Accuray. The move to take service in-house provides new opportunities for growth and further market penetration for both the CyberKnife and TomoTherapy systems in Japan. Accuray forecasts that the transfer of the service business from Hitachi Medical to Accuray will drive an increase in service revenue.
Accuray and Hitachi Medical will continue to partner on sales and distribution, enabling Accuray to benefit from Hitachi Medical's deep territory penetration in the Japan's radiation oncology market. Accuray expects the relationship to also provide opportunities for future growth of the TomoTherapy business globally.
For more information: www.accuray.com
March 28, 2024 
